Indian companies may soon start manufacturing the obesity drug Wegovy and diabetes drug Ozempic with support from the government’s production-linked incentive (PLI) scheme. This will follow the expiring of Novo Nordisk’s patent on semaglutide drugs in India by 2026.
“Drugmakers globally are eager to tap into the weight-loss drug market, which is projected to reach $100bn by the decade’s end.”